GT
IONS icon

Glenmede Trust’s Ionis Pharmaceuticals IONS Stock Holding History

Glenmede Trust’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-200
Closed -$9K – 1716
2020
Q3 		$9K Hold
200
– – ﹤0.01% 1915
2020
Q2 		$11K Sell
200
-446
-69% -$24.8K ﹤0.01% 1826
2020
Q1 		$38K Hold
646
– – ﹤0.01% 1802
2019
Q4 		$38K Buy
646
+440
+214% +$26.2K ﹤0.01% 1802
2019
Q3 		$11 Hold
206
– – ﹤0.01% 2317
2019
Q2 		$12 Hold
206
– – ﹤0.01% 2285
2019
Q1 		$16 Sell
206
-15
-7% -$968 ﹤0.01% 2175
2018
Q4 		$11 Buy
221
+21
+11% +$1.07K ﹤0.01% 2230
2018
Q3 		$10K Buy
+200
New +$9.4K ﹤0.01% 1382
2018
Q2 		– Sell
-200
Closed -$10K – 2117
2018
Q1 		$10K Hold
200
– – ﹤0.01% 2177
2017
Q4 		$10K Hold
200
– – ﹤0.01% 2177
2017
Q3 		$10K Sell
200
-524
-72% -$27.4K ﹤0.01% 2178
2017
Q2 		$29K Hold
724
– – ﹤0.01% 1799
2017
Q1 		$29K Buy
724
+14
+2% +$629 ﹤0.01% 1799
2016
Q4 		$33K Hold
710
– – ﹤0.01% 1737
2016
Q3 		$25K Sell
710
-1,000
-58% -$31.3K ﹤0.01% 1865
2016
Q2 		$38K Buy
1,710
+1,600
+1,455% +$51.6K ﹤0.01% 1668
2016
Q1 		$4K Hold
110
– – ﹤0.01% 2271
2015
Q4 		$6K Hold
110
– – ﹤0.01% 2211
2015
Q3 		$4K Buy
110
+25
+29% +$1.29K ﹤0.01% 2360
2015
Q2 		$4K Sell
85
-3,600
-98% -$229K ﹤0.01% 2284
2015
Q1 		$234K Sell
3,685
-400
-10% -$27.1K ﹤0.01% 1202
2014
Q4 		$251K Hold
4,085
– – ﹤0.01% 1203
2014
Q3 		$158K Sell
4,085
-3,623
-47% -$128K ﹤0.01% 1261
2014
Q2 		$265K Buy
7,708
+4,100
+114% +$129K ﹤0.01% 1075
2014
Q1 		$155K Buy
3,608
+400
+12% +$19.4K ﹤0.01% 1266
2013
Q4 		$127K Buy
3,208
+408
+15% +$14.5K ﹤0.01% 1317
2013
Q3 		$105K Sell
2,800
-60
-2% -$1.79K ﹤0.01% 1355
2013
Q2 		$76K Buy
+2,860
New +$60.8K ﹤0.01% 1408

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Glenmede Trust's IONS Position: Q4 2020 in Review

Glenmede Trust sold out of Ionis Pharmaceuticals (IONS) in Q4 2020, closing a stake of 200 shares — an estimated $9K sold.

Glenmede Trust first reported a position in IONS in Q2 2013 and held it in 29 quarters. The position peaked at $265K in Q2 2014. 382 funds tracked by Wall St. Rank hold IONS as of Q4 2020.

  • Glenmede Trust reported no remaining Ionis Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 200 Ionis Pharmaceuticals shares in Q4 2020, an estimated $9K.
  • Glenmede Trust first reported a position in Ionis Pharmaceuticals in Q2 2013 and held it in 29 quarters.
  • Glenmede Trust's Ionis Pharmaceuticals position peaked at $265K in Q2 2014.
  • 382 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.